PVI
SNDX icon

Pura Vida Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Pura Vida Investments’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100,000
Closed -$548K – 107
2018
Q3 		$808K Buy
+100,000
New +$713K 0.17% 90

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pura Vida Investments's SNDX Position: Q4 2018 in Review

Pura Vida Investments sold out of Syndax Pharmaceuticals (SNDX) in Q4 2018, closing a stake of 100,000 shares — an estimated $548K sold.

Pura Vida Investments first reported a position in SNDX in Q3 2018 and held it in 1 quarter. The position peaked at $808K in Q3 2018. 74 funds tracked by Wall St. Rank hold SNDX as of Q4 2018.

  • Pura Vida Investments reported no remaining Syndax Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Pura Vida Investments sold 100,000 Syndax Pharmaceuticals shares in Q4 2018, an estimated $548K.
  • Pura Vida Investments first reported a position in Syndax Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Pura Vida Investments's Syndax Pharmaceuticals position peaked at $808K in Q3 2018.
  • 74 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2018.

Based on Pura Vida Investments's 13F filing for Q4 2018, filed 14 Feb 2019.